This listing of claims will replace all prior versions in the application:

Listing of Claims:

1. (previously presented) A composition capable of inducing an immune response in a mammal to cytotoxic T cell epitopes of a full length viral protein wherein the composition comprises a unit dose of *Bacillus anthracis* anthrax protective antigen (PA) and said full length viral protein bound to an anthrax protective antigen binding protein (APABP),

wherein the APABP comprises at least about the first 250 amino acid residues of the lethal factor (LF) of *Bacillus anthracis* and less than all of the amino acid residues of the lethal factor, and

wherein said unit dose is an amount sufficient to elicit an MHC class I-mediated cytotoxic T lymphocyte immune response specific for the viral protein.

2. (previously presented) The composition of claim 1 wherein the PA is a processed PA.

3. (previously presented) The composition of claim 1 wherein the composition is sterile.

4. (previously presented) The composition of claim 1 wherein the composition further comprises physiologically compatible salts.

5. (previously presented) The composition of claim 4 wherein the composition is in an aqueous solution of physiologically compatible salts.

6. (previously presented) The composition of claim 1 wherein the APABP is the lethal factor of *Bacillus anthracis*.

7.-29 (canceled)

30. (previously presented) The composition of claim 1, wherein the full length viral protein is selected from the group consisting of: a cytomegalovirus (CMV) protein, a

hepatitis C protein, a human immunodeficiency virus (HIV) protein, herpes simplex virus protein NS-5b, and a feline immunodeficiency virus (FIV) protein.

31. (previously presented) The composition of claim 1, wherein the molar ratio of PA to the full length viral protein bound to the APABP is greater than one.